{"DataElement":{"publicId":"3253413","version":"1","preferredName":"Kaposi Sarcoma Response Code","preferredDefinition":"Code to signify the response of a patient with Kaposi's Sarcoma (KS) to treatment.","longName":"KS_RESP_CD","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2639459","version":"1","preferredName":"Kaposi Sarcoma Agent Response","preferredDefinition":"information relating to the response of a patient's Kaposi Sarcoma (a malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells) to treatment with an agent.","longName":"KS_AGT_RESPONSE","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2639367","version":"1","preferredName":"Kaposi Sarcoma","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","longName":"C9087","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"30BF3151-5EE1-1E4A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-18","modifiedBy":"ONEDATA","dateModified":"2007-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2639457","version":"1","preferredName":"Agent Response","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"C1708:C25755","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"30C133F4-3AC4-5BE4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-18","modifiedBy":"ONEDATA","dateModified":"2007-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"30C133F4-3AD5-5BE4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3253407","version":"1","preferredName":"Kaposi Sarcoma Response Code","preferredDefinition":"information related to a Kaposi Sarcoma response type._A system of numbered categories for representation of data.","longName":"KS_RESP_CD","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"6","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"SKSD","valueDescription":"Stable KS Disease","ValueMeaning":{"publicId":"3253408","version":"1","preferredName":"Stable KS Disease","longName":"3253408","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).: Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A80C21D3-E7A6-4D9C-E040-BB89AD435885","latestVersionIndicator":"Yes","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A80C21D3-E7BF-4D9C-E040-BB89AD435885","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"ONEDATA","dateModified":"2011-07-14","deletedIndicator":"No"},{"value":"PKSD","valueDescription":"Progressive KS Disease","ValueMeaning":{"publicId":"3253409","version":"1","preferredName":"Progressive KS Disease","longName":"3253409","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).: Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A80C21D3-E7CC-4D9C-E040-BB89AD435885","latestVersionIndicator":"Yes","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A80C21D3-E7E5-4D9C-E040-BB89AD435885","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"ONEDATA","dateModified":"2011-07-14","deletedIndicator":"No"},{"value":"PKSR","valueDescription":"Partial KS Response","ValueMeaning":{"publicId":"3253410","version":"1","preferredName":"Partial KS Response","longName":"3253410","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).: A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A80C21D3-E7F2-4D9C-E040-BB89AD435885","latestVersionIndicator":"Yes","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A80C21D3-E80B-4D9C-E040-BB89AD435885","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"ONEDATA","dateModified":"2011-07-14","deletedIndicator":"No"},{"value":"CCKSR","valueDescription":"Clinical Complete KS Response","ValueMeaning":{"publicId":"3253411","version":"1","preferredName":"Clinical Complete KS Response","longName":"3253411","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).: Having to do with the examination and treatment of patients.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A80C21D3-E819-4D9C-E040-BB89AD435885","latestVersionIndicator":"Yes","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A80C21D3-E832-4D9C-E040-BB89AD435885","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"ONEDATA","dateModified":"2011-07-14","deletedIndicator":"No"},{"value":"CKSR","valueDescription":"Complete KS Response","ValueMeaning":{"publicId":"3253412","version":"1","preferredName":"Complete KS Response","longName":"3253412","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A80C21D3-E83F-4D9C-E040-BB89AD435885","latestVersionIndicator":"Yes","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A80C21D3-E858-4D9C-E040-BB89AD435885","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"ONEDATA","dateModified":"2011-07-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261841","version":"1","preferredName":"Code","preferredDefinition":"A system of numbered categories for representation of data.","longName":"C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-6427-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-07-13","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A80C21D3-E78F-4D9C-E040-BB89AD435885","latestVersionIndicator":"Yes","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"REEVESD","dateModified":"2011-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"KS Response","type":"Preferred Question Text","description":"KS Response","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A80C21D3-E882-4D9C-E040-BB89AD435885","latestVersionIndicator":"Yes","beginDate":"2011-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-14","modifiedBy":"REEVESD","dateModified":"2011-07-14","changeDescription":"Curated for NCI CCR clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}